Titlebook: Dyslipidemias; Pathophysiology, Eva Abhimanyu Garg Book 2015 Humana Press 2015 Abetalipoproteinemia.Chronic kidney disease.Drug-induced dys

INCUR

stressors

案發(fā)地點

Epidemiology of Blood Lipids and Lipoproteins,gher levels generally confer greater risk for cardiovascular disease (CVD) events. The key determinants for higher levels of atherogenic lipids measured as low-density lipoprotein cholesterol (LDL-C) include high dietary saturated fat, high dietary cholesterol, and low dietary polyunsaturated fat. T

watertight,

顯赫的人

Lipoproteins and Cardiovascular Disease Risk,ting lipoprotein fractions, an individual’s CVD risk is also influenced by the concomitant presence or absence of other standard CVD risk factors. In this chapter, we describe the strengths and weaknesses of common circulating lipoproteins that are measured in clinical practice for predicting CVD ri

控訴

FLOUR

Type 2 Diabetes Mellitus and Dyslipidemia,. Dyslipidemia in type 2 diabetes is characterized by elevated levels of plasma total and very-low-density lipoprotein triglycerides and postprandial triglyceride-rich lipoprotein remnants, abundance of small dense low-density lipoprotein (LDL) particles, low levels of HDL cholesterol, and elevated

有危險

Type 1 Diabetes Mellitus and Dyslipidemia,k factor. The pathophysiology of dyslipidemia in T1D is frequently a function of insulin deficiency and poor glycemic control or peripheral hyperinsulinization in intensive control (with obesity as a potential contributor). As such, intensive diabetes control to achieve near euglycemia with a health

不安

Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome,idney disease and proteinuria are associated with cardiovascular disease and profound alteration of lipid metabolism and serum lipid and lipoprotein profile. The associated lipid disorders play a major role in progression of renal and cardiovascular disease in this population. The nature and mechani

1分開